ELAB PMGC Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1840563 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-98.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin27.5%
Operating margin—
Net margin-275.7%
FCF margin-207.8%
EBITDA margin—
Returns
ROE-129.1%
ROA-18.0%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets15.8%
Debt / equity0.00x
Current ratio1.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue21.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.53M | $1.31M | $681,994 | $304,136 | $285,948 | — | — | — |
| Cost of revenue | $1.93M | $920,919 | $451,520 | $196,852 | $207,918 | — | — | — |
| Gross profit | $601,444 | $385,691 | $230,474 | $107,284 | $78,030 | — | — | — |
| R&D expense | $130,261 | $310,219 | $47,061 | $32,902 | $15,000 | $66,675 | $5,832 | -$164,132 |
| SG&A expense | $1.90M | $1.61M | $1.38M | $983,247 | $726,543 | $319,839 | $209,031 | -$1.00M |
| Operating income | — | — | — | — | -$2.20M | — | — | — |
| Interest expense | $488,385 | $582,241 | $474,170 | $229,753 | $17,401 | $2 | $10,474 | $32,522 |
| Net income | -$2.41M | -$2.94M | -$4.97M | -$2.98M | -$2.59M | -$562,355 | -$1.61M | -$1.93M |
| EBITDA | — | — | — | — | -$2.16M | — | — | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $113.40M | $18.14M | $14.35M | $5.40M | $7.70M | $5.68M | $5.36M | $3.98M |
| Short-term investments | $548,029 | $650,598 | $733,405 | $572,054 | $804,070 | $624,838 | $557,375 | — |
| Receivables | $1.23M | $421,859 | $428,106 | $245,423 | $271,492 | — | — | $5,276 |
| Inventory | $930,234 | $932,508 | $253,558 | $95,098 | $128,469 | — | — | — |
| Current assets | $16.56M | $20.83M | $16.39M | $6.87M | $9.77M | $7.30M | $6.82M | $6.05M |
| PP&E, net | $2.20M | $1.90M | $1.75M | $885,520 | $413,446 | — | — | $1,087 |
| Goodwill | $3.04M | $3.04M | $1.86M | $977,774 | $959,535 | — | — | — |
| Intangibles | $5.73M | $5.99M | $3.80M | $2.89M | $2.55M | $2.07M | $2.07M | $2.80M |
| Total assets | $133.10M | $36.56M | $26.03M | $12.87M | $14.94M | $9.38M | $8.89M | $8.99M |
| Current liabilities | $13.03M | $15.33M | $11.30M | $3.94M | $5.46M | $326,301 | $760,268 | $1.80M |
| Total liabilities | $21.03M | $19.83M | $13.43M | $5.03M | $6.45M | $326,301 | $760,268 | $2.33M |
| Shareholders' equity | $12.11M | $16.74M | $12.61M | $7.84M | $8.49M | $9.05M | $8.13M | $6.66M |
| Shares outstanding | 889,586 | 6.15M | 1.94M | 8,070 | 744,121 | 1.48M | 707,076 | 5,226 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.26M | -$1.99M | -$2.98M | -$1.75M | -$1.49M | -$1.35M | -$1.35M | -$2.00M |
| Capital expenditure | $361,426 | -$27,569 | $363,087 | $346,661 | — | — | — | $0 |
| Free cash flow | -$2.62M | -$1.96M | -$3.34M | -$2.10M | — | — | — | -$2.00M |
| Investing cash flow | -$757,337 | -$3.68M | -$2.48M | -$548,642 | -$2.20M | $196,840 | -$215,319 | -$439,084 |
| Financing cash flow | $98.28M | $9.46M | $14.41M | -$1 | $5.71M | $1.47M | $2.94M | -$1 |
| Depreciation & amortization | $284,805 | $281,237 | $159,444 | $59,756 | $35,284 | $20 | $1,085 | $134 |
| Stock-based compensation | $355,363 | $174,545 | $8,216 | $10,657 | $13,179 | $15,842 | -$58,838 | $39,646 |
Free plan shows the latest 8 periods; Pro shows all 17 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.